Trials / Completed
CompletedNCT03461757
Trial in Adult Subjects With Acute Migraines
BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,811 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | 75 mg ODT QD |
| DRUG | Placebo | Placebo ODT to match rimegepant dose QD |
Timeline
- Start date
- 2018-02-27
- Primary completion
- 2018-10-08
- Completion
- 2018-10-15
- First posted
- 2018-03-12
- Last updated
- 2023-02-16
- Results posted
- 2020-03-27
Locations
69 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03461757. Inclusion in this directory is not an endorsement.